Skip to content

Services
Technologies
Knowledge Center
About

Connect with an Expert

Services
Technologies
- TESSA^® Scalable AAV Production
- XOFLX^™ Packaging and Producer Cell Lines
Knowledge Center
About

Connect with an Expert

WuXi Advanced Therapies Receives FDA Approval To Manufacture Iovance’s AMTAGVI (Lifileucel) For Advanced Melanoma

Post navigation

Previous: WuXi Advanced Therapies’ Philadelphia Site Approved by FDA to Start Manufacturing Iovance’s Melanoma T-cell Therapy

Next: FDA approval of cancer treatment provides new weapon against tumors

Search

Recent Posts

Pioneering Scalable Solutions in AAV Manufacturing and Testing for Gene Therapy
Five Best Practices to Adapt and Improve Quality Control Programs for CGTs
6 Key Questions to Cover When Selecting Your Cell Banking Manufacturing Partner
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance’s AMTAGVI^™ (lifileucel) for Advanced Melanoma
WuXi Advanced Therapies Supports First Investigational CD19 CAR-T Therapy Approved by China’s NMPA

Recent Comments

No comments to show.

Archives

June 2024
April 2024
February 2024
November 2023
August 2023
June 2023
March 2023
August 2022
January 2022

Categories

Article
Brochure
Case Study
Events
Poster
Video
Webinar

Services
Technologies
- TESSA®️ Scalable AAV Production
- XOFLX™ Packaging and Producer Cell Lines
Knowledge Center
About

Stay Connected with Us on Social Media

WuXi Advanced Therapies HQ

4751 League Island Blvd, Philadelphia, PA 19112 © 2024 Wuxi Advanced Therapies. All rights reserved.

Privacy Policy By using this site, you agree to our Cookie Policy.

Stay Updated

Ameba Creative Studio